title: [Use of trental for correction of disorders in the system of hemostasys in patients with fibro-cavernous tuberculosis and chronic pulmonary heart].
abstract: The effect of trental on hemostasys system depending on the degree of heart failure was studied in patients with fibrocavernous pulmonary tuberculosis complicated by chronic pulmonary heart disease. Established the desirability of placing trental in the treatment regimen of patients with fibrocavernous pulmonary tuberculosis and compensated CPHD in order to correct violations of the microcirculation and prevention of circulatory decompensation.
authors.forename: R S
authors.initials: RS
authors.lastname: Aliev
authors.forename: F F
authors.initials: FF
authors.lastname: Agaev
authors.forename: L P
authors.initials: LP
authors.lastname: Alieva
mesh_terms: D000991:Antithrombins / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D002449:Cell Aggregation / Q000187:drug effects; D005337:Fibrin / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008168:Lung / Q000098:blood supply* / Q000473:pathology; D010431:Pentoxifylline / Q000627:therapeutic use*; D010976:Platelet Count; D011660:Pulmonary Heart Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000150:complications / Q000188:drug therapy*
chemical_list: D000991:Antithrombins; D005337:Fibrin; D005340:Fibrinogen; D010431:Pentoxifylline